This research falls within the rapidly evolving field of cancer immunotherapy and nanomedicine, specifically focusing on cytokine-based therapeutic approaches. The study addresses a critical challenge in IL-12 cytokine therapy - the immunosuppressive feedback mechanisms that limit its therapeutic efficacy1. IL-12 has demonstrated potent antitumor activity in preclinical models by promoting T helper type 1 (TH1) differentiation and enhancing cytotoxic T lymphocyte activity. Ho